IL-2 has both immunostimulative and immunosuppressive functions37, but the administration of low-dose IL-2 or IL-2/anti-IL-2 antibody immunocomplexes with an increased half-life of IL-2 led to an increase in circulating regulatory CD4 + T lymphocytes (Tregs), which protected against CKD in animal experiments38. The gene discussed is CD4; the disease is chronic kidney disease.